Trexquant Investment LP Has $3.50 Million Holdings in Dyne Therapeutics, Inc. $DYN

Key Points

• Trexquant Investment LP has significantly increased its holdings in Dyne Therapeutics, now owning 334,443 shares worth approximately $3.50 million after a purchase of 209,065 shares in the first quarter.
• Several institutional investors have also raised their stakes in Dyne Therapeutics, with hedge funds collectively owning 96.68% of the company's stock.
• Analysts maintain a generally positive outlook on Dyne Therapeutics, with a consensus rating of "Buy" and a price target averaging around $34.07 per share.

Trexquant Investment LP grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 166.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 334,443 shares of the company's stock after buying an additional 209,065 shares during the quarter. Trexquant Investment LP owned 0.29% of Dyne Therapeutics worth $3,498,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Comerica Bank boosted its holdings in shares of Dyne Therapeutics by 16.3% in the first quarter. Comerica Bank now owns 41,176 shares of the company's stock valued at $431,000 after buying an additional 5,767 shares during the period. Walleye Capital LLC acquired a new position in shares of Dyne Therapeutics in the first quarter valued at approximately $1,617,000. Atlas Venture Life Science Advisors LLC boosted its holdings in Dyne Therapeutics by 13.9% during the first quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company's stock worth $95,505,000 after purchasing an additional 1,111,111 shares during the last quarter. AlphaQuest LLC acquired a new position in Dyne Therapeutics during the first quarter worth $171,000. Finally, Candriam S.C.A. boosted its holdings in Dyne Therapeutics by 15.4% during the first quarter. Candriam S.C.A. now owns 463,368 shares of the company's stock worth $4,847,000 after purchasing an additional 61,973 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on DYN shares. Jones Trading started coverage on shares of Dyne Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $30.00 target price for the company. Raymond James Financial upgraded shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $31.00 to $35.00 in a report on Monday, August 25th. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Sanford C. Bernstein started coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 target price for the company. Finally, Chardan Capital reduced their target price on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $34.07.

Insider Buying and Selling at Dyne Therapeutics

In related news, CEO John Cox acquired 100,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were bought at an average cost of $9.11 per share, with a total value of $911,000.00. Following the completion of the transaction, the chief executive officer directly owned 242,179 shares of the company's stock, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $13.50 on Wednesday. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The firm's fifty day moving average price is $10.57 and its two-hundred day moving average price is $11.15. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $37.08. The firm has a market capitalization of $1.92 billion, a P/E ratio of -3.50 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.02. As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.